Fiat Justitia

          Justice is what you do.

          Why We Work For Justice
          The UC Hastings seal carries the words fiat justitia -- Let Justice Be Done. This motto is not a hollow promise; it is who we are and what we do.

          School Spirit

          Engaged Scholarship

          After 138 years of teaching law and producing first-class legal scholarship, we began to wonder if perhaps we are just a little too focused. Maybe we should look a little more like other institutions...

          Legally Speaking

          In conversation with UC Hastings Professor Joan C. Williams.

          UC Hastings Professor Joan Williams welcomes U.S. Supreme Court Associate Justice Ruth Bader Ginsburg for a conversation that touches on a broad range of subjects, from opera to marriage to work/life balance, doctrinal questions, and cases from the 1970's to present, including the court's role in establishing individual rights and equal protection. 
          Thursday, April 19, 2018

          Shadowy World of Drug Pricing—An Inside Look

          New research by University of California Hastings Law Professor Robin Feldman shines light on the highly secretive world of drug prices, including hidden payments, rebates, and inducements that drive the system toward higher-priced drugs.

          Sample alt tag.
          Research by Professor Robin Feldman illustrates how incentives structures in which higher-priced drugs receive favorable treatment and patients are channeled into more expensive medicines.
          As President Trump reportedly plans to deliver his first major speech on pharmaceutical pricing, new research published by University of California Hastings Law Professor Robin Feldman provides a full picture of the incentives structures in which higher-priced drugs receive favorable treatment and patients are channeled into more expensive medicines.
          In Perverse Incentives: Why Everyone Prefers High Drug Prices—Except for Those Who Pay the Bills, Professor Feldman expands on her findings from Drug Wars: How Big Pharma Raises Prices and Keeps Generics off the Market, Cambridge University Press (July 2017), to detail “how drug companies use financial incentives, structured in different ways to appeal to hospitals, insurers, doctors, and even patient advocacy groups, to ensure that lower-priced substitutes cannot gain a foothold.”
          “It’s a win-win for everyone,” says Feldman, “except of course taxpayers and society.”
          At the center, Feldman explains, lies the secretive and concentrated Pharmacy Benefit Manager (PBM) industry—middle players functioning as shadow brokers who negotiate between drug companies and health insurers by arranging for rebates and establishing coverage levels for patients.
          “Contracts between drug companies and other middle players are closely guarded secrets. Payors including, Medicare, private health insurer companies, and even their auditors, generally are not permitted access to the terms. And the middle players are not alone. Everyone is feeding at the trough. Despite the extreme secrecy, details regarding the competitive distortions of the pharmaceutical market are beginning to seep out in case documents and other reports.”

          Following are allegations in cases recently filed or settled:

          • Documents unsealed in a class action lawsuit against the manufacturer of the psychiatric drug Zyprexa, suggesting that the middle player’s combination with one of the largest pharmacies in the country allowed it to use data-driven ad targeting to market its drug. Documents show CVS Caremark (a combined PBM and pharmacy) offering to send a letter to 120,000 doctors—targeted based on claims information—touting the benefits of Zyprexa. Letter carefully worded to look like simple information on the benefits of Zyprexa, downplaying reports of side effects, and pointing to similar side effects in other drugs. (Text of letter available).
          • Class action suits filed in 2017 against Walgreens and CVS alleging that pharmacies charged covered patients more than the uninsured when purchasing certain generic drugs, as part of a scheme to ensure higher payments to the middle players and enhance the brand’s market position.
          • Drug company donations to patient advocacy groups and patient assistance programs. Studies show that the majority of patient advocacy groups receive significant support from drug and device companies, which may influence the groups to advocate for policies favorable to the company. Donations of one’s own drug are particularly tax advantaged—the company gets a deduction above the cost of the drug—and patient assistance programs are 10 of the largest 15 charitable foundations in the US.
          • Lawsuit against Sanofi for tactics related to its pediatric meningitis vaccine. Case alleged that Sanofi charged 34% higher prices for the vaccine, unless buyers agreed to buy all of Sanofi’s vaccines exclusively.
          • 2017 lawsuit filed alleging J&J tried to suppress competition for its inflammation drug, Remicade, using payments to hospitals and health insurance plans to exclude the less expensive biosimilar completely or cover the competing drug only in the rarest of circumstances. As a result, hospitals declined to stock the biosimilar, even though covered by government programs, forcing the government to pay for the more expensive drug.

           Research for Perverse Incentives: Why Everyone Prefers High Drug Prices—Except for Those Who Pay the Bills was supported by a generous grant from the Laura and John Arnold Foundation. The paper can be accessed via SSRN:

          Links to other papers of Professor Feldman’s on the pharmaceutical industry:


          Alex A.G. Shapiro
          Director of External Relations
          UC Hastings College of the Law
          Office: (415) 581-8842
          Cell: (415) 813-9214


          Go to News Archive

          Share this Story

          Share via Facebook
          Share via TwitterShare via EmailPrint Friendly Version

          Other Recent Stories/ RSS

          Friday, May 18, 2018

          UC Hastings Students Speak at UN Human Rights Council in Geneva

          Members of the Hastings Human Rights and International Law Organization attended the 37th Session of the United Nations Human Rights Council to meet diplomats, engage in discussions on human rights issues, and deliver advocacy statements during proceedings.
          Wednesday, May 09, 2018

          Joseph W. Cotchett, Champion for Justice and Titan of the Plaintiffs Bar, is UC Hastings Law's 2018 Commencement Speaker

          Litigation Trial Lawyers Hall of Famer and UC Hastings Alumnus, Class of 1964, to keynote the College’s 137th Commencement
          Friday, May 04, 2018

          Blek le Rat, “The Godfather” of Stencil Graffiti, Contributes Installation at UC Hastings

          The innovative street artist is taking to the streets with works throughout San Francisco to promote a rare North American exhibition.
          Friday, May 04, 2018

          UC Hastings Professor Veena Dubal’s Work Plays Role in California Supreme Court Ruling

          “The Dynamex Decision” creates a major change in the landscape for California’s gig economy and follows the path of Professor Dubal’s analysis from her scholarly work.
          Wednesday, May 02, 2018

          Thinkers & Doers: April 2018

          Professor Dubal cited in the California Supreme Court’s Dynamex decision – Professor Aviram discusses “Sanctuary City” litigation outside the Ninth Circuit – Ellen DeGeneres asks Kamala Harris about 2020 presidential aspirations – How Asylum Works and Doesn’t Work – Professor Ball earns national recognition with 2018 Shanara Gilbert Award – Highlights from the Spring Soirée – and much more
          Go to News Archive